Regeneron Pharmaceuticals (REGN) Set to Announce Quarterly Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) will likely be issuing its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect Regeneron Pharmaceuticals to announce earnings of $16.36 per share and revenue of $4.56 billion for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $12.81 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $49.10 EPS for the current fiscal year and $53.12 EPS for the next fiscal year.

Regeneron Pharmaceuticals Trading Up 1.0%

Shares of REGN opened at $816.10 on Wednesday. The firm has a fifty day simple moving average of $791.66 and a two-hundred day simple moving average of $737.08. The firm has a market cap of $84.02 billion, a PE ratio of 20.17 and a beta of 0.16. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $859.34.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insiders Place Their Bets

In related news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is owned by company insiders.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its Ebola treatment. The extension adds approximately $270 million in value and supports near-term revenue visibility. Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness
• Positive Sentiment: Strong third-quarter results from partner Kiniksa highlighted growing demand and blockbuster potential for Arcalyst, which is partnered with Regeneron. The update may reinforce expectations for increased royalty or collaboration-related contributions. Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
• Positive Sentiment: Regeneron released nearly four years of survival-benefit data for Libtayo, its cancer immunotherapy. Durable efficacy could support the drug’s commercial positioning and future adoption. Regeneron Pharmaceuticals Posts Nearly Four Years of Survival Benefit Data for Libtayo
• Neutral Sentiment: Analysts expect third-quarter earnings of approximately $16.19 per share, with results due October 30. Investors are also focused on Regeneron recording its full share of Dupixent profits with Sanofi for the first time, a potentially significant earnings catalyst but one already receiving attention ahead of the report. Regeneron Q3 earnings preview
• Neutral Sentiment: Recent commentary describes REGN as an increasingly diversified investment and a strong value stock. Reported short interest of zero shares provides no meaningful bearish signal, although the figure may reflect a data-reporting issue rather than actual market positioning. Has Regeneron Stock Become a Different Bet?

Analysts Set New Price Targets

REGN has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Leerink Partners boosted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Finally, UBS Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $660.00 to $978.00 in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $846.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.